BioNTech says it will start cancer vaccine trials in the UK from September

Cancer patients in England will get early access to trials involving personalized mRNA therapies, including cancer vaccines, which aim to spur the immune system to attack harmful cells.

They will be administered to early and late-stage patients and target both active cancer cells and preventing their return.

BioNTech will set up new research and development centers in the UK, with a lab in Cambridge and headquarters in London, and aim to deliver 10,000 therapies to patients from September 2023 until the end of the decade.

The company developed one of the most widely-distributed Covid-19 vaccines alongside US pharma firm Pfizer, Its CEO, Ugur Sahin, said it had learned lessons from the coronavirus pandemic about collaboration between the British National Health Service, academics, regulators and the private sector in the development of drugs that it was applying now.

“Our goal is to accelerate the development of immunotherapies and vaccines using technologies we have been researching for over 20 years,” he said in a statement. “The collaboration will cover various cancer types and infectious diseases affecting collectively hundreds of millions of people worldwide.”

Peter Johnson, Britain’s National Clinical Director for Cancer, said mRNA technology had the potential to transform approaches to a number of diseases.

The government confirmed to CNBC the announcement represented a private investment into the UK, but would be supported by a new Cancer Vaccine Launch Pad funded by the NHS.

Other mRNA cancer vaccines, including a collaboration between US firms Moderna and merckare also being trialled.

Tim Bierley, a campaigner at UK-based group Global Justice Now, said big pharmaceutical companies had a “terrible record of price gouging on new medicines, even where public money has played a key role in bringing them to the market.”

“The government has a moral duty to push BioNtech to set the price of this potentially life-saving vaccine so it is accessible to all,” he said.

Mohga Kamal-Yanni, policy co-lead for the People’s Vaccine Alliance — a global group of health organizations, economists and activists — said news of the trial was good, but that any outcome “belongs to the people” due to the amount of public funding involved.

“The UK government must say how it will ensure any new medicine, vaccine or technology will be made available and affordable to developing countries,” Kamal-Yanni said.

A government spokesperson told CNBC the research was at too early a stage to discuss pricing and distribution, but pointed to its record in distributing free Covid-19 vaccines.